Major Histocompatibility Complex 2017; 24 (3): II MHC MHC Precision Medicine HLA personalized medicine precision medicine

Size: px
Start display at page:

Download "Major Histocompatibility Complex 2017; 24 (3): II MHC MHC Precision Medicine HLA personalized medicine precision medicine"

Transcription

1 HLA-QC HLA HLA HLA HLA HLA 198 J.J. van Rood MHC Major Histocompatibility Complex Official Journal of Japanese Society for Histocompatibility and Immunogenetics JSHI

2 Major Histocompatibility Complex 2017; 24 (3): II MHC MHC Precision Medicine HLA personalized medicine precision medicine TEL: QCWS HLA II TEL: jshi2018@shinshu-u.ac.jp QCWS

3 Major Histocompatibility Complex 2017; 24 (3): MHC

4 30 MHC 2017; 24 (3) hlajimu@m.u-tokyo.ac.jp 1 A4 1 FAX 2 A A FAX

5 MHC 2017; 24 (3) hlajimu@m.u-tokyo.ac.jp 2 3 MHC hlajimu@m.utokyo.ac.jp 174

6 Major Histocompatibility Complex 2017; 24 (3): HLA-QC QC HLA-QC 22nd.QCWS QCWS QC DNA HP CD QCWS 2 QCWS QCWS jshiqcws@jrc.or.jp 3 QCWS FAX PDF 4 QCWS 6,000 1 hlajimu@m.u-tokyo.ac.jp 5 QCWS QCWS QCWS QCWS QCWS QCWS 2, QCWS 2,000 3 QCWS QCWS

7 MHC 2017; 24 (3) 22 HLA-QC QCWS 22 QCWS QCWS FAX:

8 22 HLA-QC MHC 2017; 24 (3) 22 HLA-QC 1 HLA-QC 2 JSHI QCWS jshiqcws@jrc.or.jp 3 1 6, HLA-QC QCWS HLA-QC 22 HLA-QC a DNA-QC a QC b DNA-QC SSP b c QC c þ d þ d e HLA f 1 DNA-QC PCR-SSP SSP DNA b DNA-QC SSP 2 QCWS d e QC QC QC DNA-QC DNA-QC QC 3 QC QC QC 177

9 MHC 2017; 24 (3) 22 HLA-QC QCWS 1 QCWS 8 2 JSHI QCWS jshiqcws@jrc.or.jp 3 1 2, HLA-QC QCWS QCWS QCWS

10 22 HLA-QC MHC 2017; 24 (3) QCWS QCWS HLA 1 QCWS QCWS HP QCWS QCWS DNA DNA QCWS ID ID QCWS QCWS HP QCWS QCWS MHC QCWS QCWS QCWS QCWS QCWS QCWS QCWS 179

11 MHC 2017; 24 (3) 22 HLA-QC QCWS ID QCWS 14 QCWS ID QCWS QCWS QCWS DNA-QC -QC 1 6,000 QCWS 2,000 QCWS FAX QCWS FAX jshiqcws@jrc.or.jp QCWS 2018 HLA HLA -QC DNA-QC DNA-QC 180

12 22 HLA-QC MHC 2017; 24 (3) QCWS QCWS QCWS QCWS QCWS QCWS QCWS QCWS QCWS QCWS QCWS QC DNA-QC QC QCWS 14thQCWS ID QCWS ID QCWS ID QCWS PDF 181

13 Major Histocompatibility Complex 2017; 24 (3): HLA TEL HLA 2 HLA HLA 3 HLA 182

14 Major Histocompatibility Complex 2017; 24 (3): HLA 1 HLA 2 HLA HLA HLA 1 HLA Certified HLA Technologist JSHI 2 HLA HT/JSHI 2 HLA 1 Certified Director for Histocompatibility JSHI 2 DH/JSHI 3 HLA 2 1 HLA 3 4 HLA HLA HLA 5 HLA HLA 2 HLA

15 MHC 2017; 24 (3) HLA HLA 6 1 HLA HLA 8 HLA HLA 1 HLA HLA 1 15,000 HLA QC 5 6 HLA HLA HLA 184

16 HLA MHC 2017; 24 (3) HLA 10 HLA 2 HLA HLA 11 HLA QC HLA HLA 1 15, HLA QC

17 MHC 2017; 24 (3) HLA , QC , HLA

18 HLA MHC 2017; 24 (3) 17 HLA 2 2 HLA HLA 5, ,000 HLA 18 HLA , , HLA 1 HLA 2 3 HLA

19 MHC 2017; 24 (3) HLA 14 HLA HLA HLA HLA HLA

20 HLA MHC 2017; 24 (3) QC HLA 5 HLA 5 10 HLA 189

21 Major Histocompatibility Complex 2017; 24 (3): HLA HLA HLA HLA 1 HLA HLA HLA

22 30 HLA MHC 2017; 24 (3) , QCWS QC

23 Major Histocompatibility Complex 2017; 24 (3): HLA HLA QC 6 HLA

24 30 MHC 2017; 24 (3) ,

25 Major Histocompatibility Complex 2017; 24 (3): HLA HLA 1 HLA QC 1 HLA QC

26 30 HLA MHC 2017; 24 (3) HLA HLA HLA 15,000 30, HLA A4 195

27 Major Histocompatibility Complex 2017; 24 (3): S17001 S17004 S17002 S17005 S HLA G17001 G17006 G17002 G17007 G17003 G17008 G17004 G17009 G17005 G S02003 S02027 S02007 S02030 S02011 S02031 S02012 S02035 S02019 S12001 S02020 S12002 S

28 MHC 2017; 24 (3) 29 HLA G02002 G02037 G02006 G02038 G02007 G02041 G02011 G02046 G02012 G02058 G02015 G07003 G02020 G07004 G02024 G07007 G02025 G12001 G02028 G12002 G02030 G12006 G

29 Major Histocompatibility Complex 2017; 24 (3): 平成 29 年度認定 HLA 検査技術者認定制度試験問題に関する報告 29 HLA 1) 2) 3) 4) 5) 1) 6) 7) 8) 1) 2) 3) 4) HLA 5) 6) 7) 8) HLA JMS HLA % 94.0% 53.3% 19.6% % 82.1% 47.8% 17.1% % 78.7% 44.8% 19.1% % 94.1% 53.2% 22.9% % 94.1% 53.2% 22.9% % 198

30 29 HLA MHC 2017; 24 (3) 平成 29 年度認定 HLA 検査技術者認定制度試験問題 正解と難問の解説 40% % 5 40% a e a 1, 2 b 2, 3 c 1, 4 d 3, 4 e 1, 5 正解 :c 45.2% b 2 HLA a e a HLA b HLA-B c HLA I d HLA e HLA-DR T 正解 :e 54.8% a 3 a e a 46 b

31 MHC 2017; 24 (3) 29 HLA c HLA 6 d NK KIR ULBP/RAET e 正解 :c 46.4% a, d 4 a e a b c d e 正解 :c 50.0% a 5 HLA I a e 1 MHC MHC 2 HLA-A MHC 3 HLA-B MHC 4 HLA-C MHC 5 HLA-G MHC a 1, 2, 3 b 1, 2, 5 c 1, 4, 5 d 2, 3, 4 e 3, 4, 5 正解 :d 81.0% a 6 HLA a e a HLA dbsnp b HLA DDBJ c HLA IMGT d HLA HapMap e HLA OMIM 正解 :c 63.1% b 7 HLA I a e a 200

32 29 HLA MHC 2017; 24 (3) b c d e 正解 :b 63.1% a 8 HLA HLA a e a HLA-DR B b HLA-A c HLA I NK d HLA MICA T e HLA-G 正解 :c 54.8% d, e 9 HLA I a e a 2 b c 9 10 d e CD8 正解 :a 54.8% c 10 MICA a e a I b KIR c NK T d e microrna 正解 :b 29.8% a, c, d, e MICA NK CD8 T T CD94/NKG2D KIR CD4 T CD94/NKG2D 201

33 MHC 2017; 24 (3) 29 HLA microrna mir b microrna-20a MICA 11 HLA I 2 a e a CD1a b HLA-F c MICA d MR1 e HFE 正解 :c 25.0% b, e MICA HLA a e 1 HLA II 2 HLA I II 3 HLA I II 4 HLA II 5 TAP a 1, 2 b 1, 3 c 2, 3 d 3, 4 e 4, 5 正解 :a 22.6% c TAP HLA I HLA I / HLA II HLA I HLA I 202

34 29 HLA MHC 2017; 24 (3) HLA I II T T 4 13 HLA a e a HLA b c d e HLA 正解 :c 39.3% b T B somatic recombination rearrangement HLA 14 HLA a e a II b I c d TAP1 TAP2 e B II 正解 :d 61.9% a, b 15 NK NKG2 a e a MIC b MIC c III d CD1d e I HLA-A,-B,-C 正解 :a 21.4% b, e MIC NKG2 NKG2D/CD94 DAP10 ULBP RAE-1 NKG2D/CD94 NKG2 203

35 MHC 2017; 24 (3) 29 HLA NKG2A/CD94 NKG2C/CD94 HLA-E DAP12 I CD1d NKT T V I NK KIR KIR3DS KIR DS 16 a e a T Th1/Th2 b c T d NK e B CD40 正解 :c 60.7% e 17 T a e 1 T 2 GVHD T 3 T CD4 T CD8 T 4 HLA T 5 HLA T a 1, 2 b 2, 3 c 2, 5 d 3, 4 e 4, 5 正解 :e 52.4% d 18 T a e MHC I- CD4 4 T MHC- 5 T CD4 CD8 a 1, 2, 3 b 1, 2, 5 c 1, 4, 5 d 2, 3, 4 e 3, 4, 5 正解 :c 66.7% b 19 MHC T TCR TCR T a e a b 204

36 29 HLA MHC 2017; 24 (3) c TCR d T e T 正解 :d 28.9% c, e affinity maturation B somatic hypermutation T TCRT MHC TCR T T T MHC T B 20 a e a b B 1 99% c d 1980 e BCG 正解 :d 82.1% e 21 a e a T b HLA c HLA T d HLA T e 正解 :d 54.2% b, c 22 a e a b c HCV 205

37 MHC 2017; 24 (3) 29 HLA d e 正解 :d 28.9% c HCV HCV 23 a e a b c d e 正解 :b 63.9% d 24 HLA T GVHD a e 1 HLA T a 1, 2, 3 b 2, 3, 4 c 1, 2, 5 d 3, 4, 5 e 2, 4, 5 正解 :b 30.1% a, e HLA GVHD T a e a b One haplotype c HLA HLA 206

38 29 HLA MHC 2017; 24 (3) d e a d 正解 :a 51.2% e 26 a e a CCI 1 3,000/μL b HLA c HLA d HLA HLA ABO e HLA HLA 正解 :d 81.0% a 27 HLA a e a HLA b HLA c HLA d HLA ABO e HLA 正解 :a 65.5% d 28 HLA a e a I HLA-DRB1*15:02 b HLA-DPB1*09:01 c HLA-B*53:01 d HLA-A*27:01 e HLA-DRB1*04:06 正解 :e 31.0% a, c, d HLA I DRB1*04:05 DRB1*15:02 I 207

39 MHC 2017; 24 (3) 29 HLA DRB1*04:05 B*51:01 HLA-B27 B*27:04 B*27:05 B*27:04 B*27:05 B*27:06 B*27:09 29 HLA a e a b c HLA d e 正解 :c 71.1% b 30 HLA a e 1 HLA 2 HLA 3 HLA 4 HLA 5 HLA a 1, 3 b 1, 4 c 2, 3 d 3, 4 e 3, 5 正解 :b 41.0% d 31 HLA a e a b c d e 2 正解 :c 33.7% e genome-wide association study; GWAS HLA HLA HLA 208

40 29 HLA MHC 2017; 24 (3) GWAS 32 a e a ABO O B b Rh Rho(+) Rho(-) c HLA A*24, A*26 A*02, A*24 d TH e MN MN M 正解 :d 83.3% b 33 a e a 2010 b c ES ips d HLA e 正解 :a 30.1% % 21.3% c ,745 47, ES ips HLA 34 ips a e a ips T b ips c ips d ips e ips HLA I 正解 :d 48.2% b 35 a e 209

41 MHC 2017; 24 (3) 29 HLA a MHC b c 1 d e 2000 正解 :d 66.3% a 36 a e a b c d e 正解 :e 16.9% a, c 37 HLA a e 1 HLA DNA 2 LCT HLA 3 SSOP HLA LCT CDC HLA 5 LCT HLA a 1, 2 b 1, 3 c 2, 4 d 2, 5 e 4, 5 正解 :a 56.0% c 38 HLA a e 1 a b a b 2 a a+b a 3 a+b a+c a b c 4 a+b a+c a 5 null allele 210

42 29 HLA MHC 2017; 24 (3) a 1, 2 b 2, 3 c 2, 4 d 3, 5 e 4, 5 正解 :b 41.7% a, c, e 39 a e a b c d HLA e HLA 正解 :d 22.6% b, c HLA HLA 40 HLA a e 1 HLA 2 3 HLA 4 HLA DNA 5 HLA HLA a 1, 2 b 2, 3 c 2, 4 d 3, 4 e 4, 5 正解 :b 61.9% d 41 MLR a e a b c d e 正解 :e 84.5% a 42 MLR a e 211

43 MHC 2017; 24 (3) 29 HLA a MLR CD4 HLA-DR T b MLR T c MLR B d MLR T e MLR T T IL-2 IFN- 正解 :d 45.8% a, b, c, e 43 HLA a e 1 RFLP 2 SSP 3 SBT HLA 4 SSOP 5 SSCP a 1, 2 b 2, 3 c 3, 4 d 3, 5 e 4, 5 正解 :b 75.0% a, c 44 PCR DNA a e a PCR DNA b PCR DNA c DNA A260/A d DNA 260 nm e DNA PCR 正解 :b 77.4% d 45 DNA a e PCR 1 2 a PCR-SSO b PCR-SSP c PCR-SSCP d PCR-RFLP e PCR-SBT 正解 :b 212

44 29 HLA MHC 2017; 24 (3) 70.2% d 46 DNA a e 1 DNA 2 PCR PCR 3 PCR 4 PCR 5 PCR a 1, 3 b 2, 4 c 1, 5 d 3, 4 e 4, 5 正解 :b 94.0% e 47 DTT a e 1 9 μl 50 mm DTT 1 μl 2 1 μl 50 mm DTT 9 μl 3 37 C 30 IgG 4 37 C 30 IgM 5 4 C 30 IgG a 1, 3 b 1, 4 c 2, 3 d 4, 5 e 1, 5 正解 :b 79.8% a 48 a e a SNP b Y c Insertion-deletion d Variable number of tandem repeats VNTR e 正解 :b 40.2% a, c, d 49 a e a CDC HLA b FCXM HLA c FCXM T I B II d LCT I e CDC 213

45 MHC 2017; 24 (3) 29 HLA 正解 :e 59.0% b, c HLA HLA-DRB1*09:01 a e a 0.22 b 0.50 c 0.78 d 1.28 e 2.00 HLA-DRB1*09:01 HLA-DRB1*09: 正解 :e 57.8% b, c 214

46 Major Histocompatibility Complex 2017; 24 (3): J.J. van Rood HLA JJ. van Rood 1973 HLA HLA II van Rood Terasaki van Rood Van Rood Dausset HLA-A2 Rose Payne LA HLA-A HLA Van Rood HLA-B 4a 4b 1) 1959 Vox Sanguinis 2) 39 C van Rood 1970 HLA-D HLA I LCT SD serologically defined HLA-D LD LD LCT LD B van Rood B LCT B HLA I LCT B HLA- I 215

47 MHC 2017; 24 (3) J.J. van Rood 3) HLA-D HLA-D HLA-DR D relatedhla- DQ B HLA II van Rood HLA van Rood 1) J.J. van Rood and A. van Leewen: Leukocyte grouping. A method and its application. J. Clin. Invest. 42: 1382, ) J.J. van Rood, A. van Leewen and J.G. Earnisse: Leucocyte antibodies in sera of pregnant women. Vox Sang. 4: 427, ) J.J. van Rood, A. van Leewen, J.J. Keuning and A.B. van Oud Alblas: The serological recognition of the human MLC determinants using a modified cytotoxicity technique. Tissue Antigens. 5: 73,

48 Major Histocompatibility Complex 2017; 24 (3): HLA JR 350 m TEL A4 1 MS 12 A yuketsu@med.kindai.ac.jp Windows Power Point Mac Power Point * yuketsu@med.kindai.ac.jp 217

49 MHC 2017; 24 (3) XXXX XXXX 1) 2) XXX 1) XX 2) 1 20 mm 25 mm 2 1 Microsoft Word 2 MS Microsoft Excel 2 218

50 219

51 Major Histocompatibility Complex 2017; 24 (3): MHC I MHC ES ips 2006 JST J-STAGE II Microsoft Word Microsoft Word Microsoft PowerPoint Microsoft PowerPoint CDR 2 1 FAX Susceptibility gene for non-obstructive azoospermia in the HLA class II region: correlations with Y chromosome microdeletion and spermatogenesis. Tetsuya Takao 1), Akira Tsujimura 1), Masaharu Sada 2), Reiko Goto 2), Minoru Koga 3), Yasushi Miyagawa 1), Kiyomi Matsumiya 1), Kazuhiko Yamada 2), Shiro Takahara 1) 220

52 MHC 2017; 24 (3) 1) Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan 2) Department of Regenerative Medicine, National Cardiovascular Center, Suita, Osaka, Japan 3) Department of Urology, Osaka Central Hospital, Osaka, Japan FlowPRA HLA 1) 1) 2) 2) 3) 1) 2) 3) words 5 cm, ml, g, Kg, pg, μl, %, C HLA-DRB words 5 3 Introduction Materials and Methods Results Discussion References cm, ml, g, Kg, pg, μl, %, C HLA-DRB1 5 3 LCT Lymphocyte cytotoxicity test et al. 1. Shi Y, Yoshihara F, Nakahama H, et al.: A novel immunosuppressant FTY720 ameliorates proteinuria and alterations of intrarenal adrenomedullin in rats with autoimmune glomerulonephritis. Regulatory Peptides 127(1 3): , Tongio M, Abbal M, Bignon JD, et al.: ASH#18: HLA-DPB1. Genetic diversity of HLA Functional and Medical Implication (ed. Charron D), Medical and Scientific International Publisher, p , IVIG 1 17(1): 36 40,

53 MHC 2017; 24 (3) 4. 6 Medical View p III Microsoft Word Microsoft Word Microsoft PowerPoint Microsoft PowerPoint CDR 2 1 FAX words IV V J8 MHC tanimoto@att.med.osaka-u.ac.jp Tel: Fax: words 400 words words

54 MHC 2017; 24 (3) MHC web 5 MHC PDF MHC HLA HLA HLA HLA URL URL umin.ac.jp/ jshi@nacos.com Tel Fax hlajimu@m.u-tokyo.ac.jp FAX jshi@nacos.com 223

MHC23-3

MHC23-3 Major Histocompatibility Complex 2016; 23 (3): 168 184 1) 2) 3) 4) 5) 1) 6) 7) 8) 1) 2) 3) 4) HLA 5) 6) 7) 8) HLA 11 25 28 10 22 1 4 61 44 6 1 10 11 5 HLA 60 3 27 3 5 9 5 10 19 5 50 22.4 5.9 8.2% 78.7%

More information

Major Histocompatibility Complex 2019; 26 (1): MHC I MHC MHC ES ips 2006 MHC JST J-STAGE MHC II 1 12, Microso

Major Histocompatibility Complex 2019; 26 (1): MHC I MHC MHC ES ips 2006 MHC JST J-STAGE MHC II 1 12, Microso Major Histocompatibility Complex 2019; 26 (1): 69 72 MHC 2019 2 12 I MHC MHC 1964 18 2013 ES ips 2006 MHC JST J-STAGE MHC II 1 12,000 12 1 400 Microsoft Word Microsoft Word Microsoft PowerPoint Microsoft

More information

日本組織適合性学会誌MHCの投稿規定

日本組織適合性学会誌MHCの投稿規定 投稿 執筆規定 (2019 年 2 月 12 日改訂 ) I. 概要内容 : MHC に関する基礎研究から臨床研究まで全てを対象にし, 未発表の論文, 他誌に投稿中 ( もしくは掲載予定 ) でないものに限る 資格 : 筆頭著者および責任著者は本学会会員であり, その他の共著者も, 原則として, 本学会会員に限る ただし,MHC 編集委員会が非会員に執筆を依頼した総説については, その限りでない 倫理

More information

MHC Vol. 19, No 平成 23 年度 日本組織適合性学会 決算報告書 自 平成 23 年 4 月 1 日 至 平成 24 年 3 月 31 日 収入の部 予算 円 決算 円 会 員 年 会 費 3,000,000 3,275, ,000 学 会 誌 広 告 費

MHC Vol. 19, No 平成 23 年度 日本組織適合性学会 決算報告書 自 平成 23 年 4 月 1 日 至 平成 24 年 3 月 31 日 収入の部 予算 円 決算 円 会 員 年 会 費 3,000,000 3,275, ,000 学 会 誌 広 告 費 MHC Vol. 19, No. 3 279 平成 23 年度 日本組織適合性学会 決算報告書 自 平成 23 年 4 月 1 日 至 平成 24 年 3 月 31 日 収入の部 予算 円 決算 円 会 員 年 会 3,, 3,275, 275, 学 会 誌 広 告 8, 6, 2, 学 会 誌 販 売 等 1, 51,895 48,15 QC ワークショップ 424, 539, 115, 講 習

More information

日本組織適合性学会誌第23巻2号

日本組織適合性学会誌第23巻2号 Major Histocompatibility Complex 2016; 23 (2): 115 122 HLA 1 1) 1) HLA MHC 1900 HLA HLA キーワード : HLA HLA HLA HLA 2 HLA HLA HLA 3 1 1 HLA HLA 図 1 2016 6 30 2016 8 2 105 0013 1 10 14 3 5 TEL: 03 5776 0048

More information

MHC Vol. 19, No 日本組織適合性学会誌 MHC の投稿規定 I. 投稿について内容 :MHC に関する基礎研究から臨床研究まで全てを対象にし, 未発表の論文, 他誌に投稿中でないものに限る 資格 : 著者 ( 共著者を含む ) は原則として本学会会員に限る 倫理 : ヒト

MHC Vol. 19, No 日本組織適合性学会誌 MHC の投稿規定 I. 投稿について内容 :MHC に関する基礎研究から臨床研究まで全てを対象にし, 未発表の論文, 他誌に投稿中でないものに限る 資格 : 著者 ( 共著者を含む ) は原則として本学会会員に限る 倫理 : ヒト 223 日本組織適合性学会誌 MHC の投稿規定 I. 投稿について内容 :MHC に関する基礎研究から臨床研究まで全てを対象にし, 未発表の論文, 他誌に投稿中でないものに限る 資格 : 著者 ( 共著者を含む ) は原則として本学会会員に限る 倫理 : ヒトおよびヒトの試料を用いた臨床研究 基礎研究の場合,1980 年ヘルシンキ宣言 ( 第 18 回 World Medical Assembly

More information

DynalTransplantDiagnostic.indd

DynalTransplantDiagnostic.indd 2011 1 SeCore HLA SBT 1 2 AllSet + Gold SSP HLA 7 3 SSP UniTray HLA 11 4 27 5 32 ii 1 SeCore HLA SBT SeCore 2 SeCore HLA SBT SeCore 3 SeCore 4 HLA-I 5 HLA-II 5 utype 5 GSSP 6 1 SeCore HLA SBT Sequencing

More information

16 MHC 2018; 25 (1) 参加費 1 2, , ,000 会議等 :00 13: :00 13: :20 会場地図 TEL JR 350 m 57

16 MHC 2018; 25 (1) 参加費 1 2, , ,000 会議等 :00 13: :00 13: :20 会場地図 TEL JR 350 m 57 Major Histocompatibility Complex 2018; 25 (1): 56 82 抄録集 16 2018 3 3 7 2 4 43 TEL 06 6962 7001 594 1101 840 TEL 0725 56 1220 56 16 MHC 2018; 25 (1) 参加費 1 2,000 2 1,000 3 3,000 会議等 1 3 3 13:00 13:10 2 3

More information

MHC 2013; 20 ( 2 QC QC DNA-QC 3. QCWS 集会参加および参加証明書発行 QCWS QCWS QCWS 解析方法 DNA-QC Luminex SSO SSO SSP SBT QC FlowPRA Lab Screen WAK Flow ICFA 4 HL

MHC 2013; 20 ( 2 QC QC DNA-QC 3. QCWS 集会参加および参加証明書発行 QCWS QCWS QCWS 解析方法 DNA-QC Luminex SSO SSO SSP SBT QC FlowPRA Lab Screen WAK Flow ICFA 4 HL Major Histocompatibility Complex 2013; 20 (: 13 16 QCWS # 1. ワークショップの経過 24 1 QCWS HP QCWS 24 2 57 DNA-QC 53 QC 38 1 20 QCWS DNA-QC QC 4 QCWS 4 4 4 16 QCWS 5 21 57 DNA-QC 53 QC 37 5 6 7 HP 8 25 HP 2. QCWS

More information

MHC 2013; 20 (1) 11 参加費 1 2, , ,000 会議等 :50 14: :30 13: :00 会場地図 参天製薬株式会社本社案内図 TEL 新大阪駅より

MHC 2013; 20 (1) 11 参加費 1 2, , ,000 会議等 :50 14: :30 13: :00 会場地図 参天製薬株式会社本社案内図 TEL 新大阪駅より Major Histocompatibility Complex 2013; 20 (1): 63 89 抄録集 11 2013 2 2 3 9 19 TEL: 06 6321 7000 630 0293 1248 1 TEL: 0743 77 0880 E-mail: tubaki@nara.med.kindai.ac.jp 63 MHC 2013; 20 (1) 11 参加費 1 2,000 2

More information

1 HLA MHC 2017; 24 (2) HLA HLA 1967 HLA HLA HLA HLA 1980 HLA HLA ABO HLA 2000 HLA DSA 2010 HLA HLA HLA HLA HLA HLA HLA HLA HLA GVHD HLA HLA

1 HLA MHC 2017; 24 (2) HLA HLA 1967 HLA HLA HLA HLA 1980 HLA HLA ABO HLA 2000 HLA DSA 2010 HLA HLA HLA HLA HLA HLA HLA HLA HLA GVHD HLA HLA Major Histocompatibility Complex 2017; 24 (2): 150 157 抄録集 1 HLA 2017 5 13 150 1 HLA MHC 2017; 24 (2) HLA 1960 1964 HLA 1967 HLA HLA HLA HLA 1980 HLA HLA ABO HLA 2000 HLA DSA 2010 HLA HLA HLA HLA HLA HLA

More information

Major Histocompatibility Complex 2018; 25 (2): 抄録集 2 HLA A 3 128

Major Histocompatibility Complex 2018; 25 (2): 抄録集 2 HLA A 3 128 Major Histocompatibility Complex 2018; 25 (: 128 138 抄録集 2018 4 14 A 3 128 MHC 2018; 25 ( HLA 2013 10.5 10 8 12 10 8 2016 CD34 + HLA NC 10 8 CD34 + CD34 + 10 6 NC10.5 2013.Apr 2014.Mar NC11 2014.Apr 2016.Jun

More information

22 S2-4 教育講演 ( 認定制度講習会 ) 9 月 14( 土 ) 10:00 ~ 12:00 座長 EL-1 EL-2 EL-3 HLA 1,2) 1) 2) HLA HLA 17th QC ワークショップ集会 9 月 14 日 ( 土 ) 13:00 ~ 16:00 タイピング結果解析 1

22 S2-4 教育講演 ( 認定制度講習会 ) 9 月 14( 土 ) 10:00 ~ 12:00 座長 EL-1 EL-2 EL-3 HLA 1,2) 1) 2) HLA HLA 17th QC ワークショップ集会 9 月 14 日 ( 土 ) 13:00 ~ 16:00 タイピング結果解析 1 22 特別講演 Ⅰ 9 月 15 日 ( 日 ) 13:40 ~ 14:40 座長 SL-1 ips 特別講演 Ⅱ( スポンサード ランチ付き ) 9 月 16 日 ( 月 ) 12:00 ~ 13:00 座長 SL-2 HLA シンポジウム Ⅰ 9 月 15 日 ( 日 ) 14:40 ~ 16:40 免疫寛容を誘導する養子免疫療法 : その基礎と臨床応用 座長 S1-1 CREST JST S1-2

More information

provider_020524_2.PDF

provider_020524_2.PDF 1 1 1 2 2 3 (1) 3 (2) 4 (3) 6 7 7 (1) 8 (2) 21 26 27 27 27 28 31 32 32 36 1 1 2 2 (1) 3 3 4 45 (2) 6 7 5 (3) 6 7 8 (1) ii iii iv 8 * 9 10 11 9 12 10 13 14 15 11 16 17 12 13 18 19 20 (2) 14 21 22 23 24

More information

スライド 1

スライド 1 DNA typing SSO & SSP Japanese Red cross fukuoka hospital HLA Hiroki Hashiguchi 2010/09/19 Tokyo -Volumea. 10μg/100μL b. 20μg/200μL (SSP) HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 ID allele #1 allele #2 allele

More information

3 6 6 8 5 5 0 4 3 4 4 0,000 3 ID ID ID 4 7 9 :5 4 5 60-8048 NACOS TEL: 075-45-366 FAX: 075-45-366 E-mail: jiao@nacos.com 3. Power Point PC 0 5. Power Point PC 7 3 3. 3 5 PC PC PC Windows Power Point USB

More information

20-第14回抄録集.indd

20-第14回抄録集.indd Major Histocompatibility Complex 2016; 23 (1): 45 71 抄録集 14 2016 2 6 7 2 4 43 TEL 06 6962 7001 HLA 600 8813 134 1 2F TEL 075 313 5201 FAX 075 313 5202 E-mail:hla@hla.or.jp 45 MHC 2016; 23 (1) 第 14 回日本組織適合性学会近畿地方会

More information

★索引.indb

★索引.indb S 703 S 704 S 705 S 706 S 707 S 708 S 709 S 710 S 711 S 712 S 713 S 714 S 715 S 716 S 717 S 718 20 4 15 Japanese Journal of Medical Ultrasonics 35 101 0063 2 23 1 6 F The Japan Society of Ultrasonics in

More information

22-3.indb

22-3.indb 22 3 27 12 20 25 113 2016 114 20 HLA-QC 117 28 HLA 123 HLA 124 28 HLA 131 28 133 28 HLA 135 27 HLA 137 27 HLA 138 原著論文 MHC I 7 156 14 164 26 166 MHC 167 170 Major Histocompatibility Complex Official Journal

More information

7... 1... 34... 55... 86... 108 15 2003 1 2 3 1 7 pdf 2 8 1996 2-1 9010 5 247 362 4 7 5 4 11 7 22 4 29 45 5 59 6 61 4 63 10 2 820 3 1646 19 1944 1 2 4 11 3 11 22 4 1 340 2 20 3 13 4 450 1 2 3 4 2-2 29

More information

日本組織適合性学会誌第20巻2号

日本組織適合性学会誌第20巻2号 Major Histocompatibility Complex 2013; 20 (2): 121 129 平成 25 年度認定 HLA 検査技術者講習会テキスト HLA 1) 1) HLA HLA HLA PRA Panel reactive antibody DSA Donor specific alloantibody class subclass non-hla HLA キーワード :Human

More information

The Plasma Boundary of Magnetic Fusion Devices

The Plasma Boundary of Magnetic Fusion Devices ASAKURA Nobuyuki, Japan Atomic Energy Research Institute, Naka, Ibaraki 311-0193, Japan e-mail: asakuran@fusion.naka.jaeri.go.jp The Plasma Boundary of Magnetic Fusion Devices Naka Fusion Research Establishment,

More information

: : BSC - - :

: : BSC - - : 2013 : : BSC - - : - - 58 30 9 70 3 3 1 Association of genetic variants of the α kinase1 gene with myocardial infarction in community dwelling individuals Abstract. ALPK1 ALPK1

More information

免疫Ⅱ

免疫Ⅱ 100 100 100 1990 127 DNA DNA DNA DNA hybridization DNA RNA DNA DNA 128 12 µδγαε 129 300 1,200 500 50012 4 24,000 1,20024,000 2.910 7 10 8 rejection major histocompatibility complex MHC MHC MHC 130 MHC

More information

PowerPoint プレゼンテーション

PowerPoint プレゼンテーション JSHI 教育講演 2018.9.23 認定制度試験問題を 中心とした HLA の解説 木村彰方東京医科歯科大学 難治疾患研究所 1 はじめに 日本組織適合性学会認定 HLA 検査技術者認定制度では 指導者および技術者の認定要件として筆記試験を課しています 昨年に引き続き 正答率が 40% 未満の問題 ( 難問 ) を中心に HLAの基礎について解説を行いますので 知識を確認してください. 2 問題

More information

I II III IV A B C V.

I II III IV A B C V. JILPT Discussion Paper 09-03 2009 4 3 2 1 1 I.... 2 II.... 3 1.... 3 2.... 4 3.... 8 4.... 9 III.... 11 1.... 12 2.... 14 3.... 17 4.... 20 IV.... 22 1. A... 23 2. B... 31 3. C... 41 4.... 49 V.... 54

More information

The 28th Annual Meeting for the Japan Society of Developmental Psychology 28 2017.3.25 27 JMS 28 28 28 2017 3 25 27 3 IT Austen Riggs Center, Erikson Dr. M. Gerard Fromm Erikson Austen Riggs Center E.H.

More information

Studies on the Antigens Expressed on Trophoblasts Related to MLR-blocking Antibodies Shigenori GOTO Department of Obstetrics and Gynecology, Niigata University School of Medicine (Director: Prof. Shoshichi

More information

:,, : - 7 -

:,, : - 7 - 31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6

More information

日本医師会雑誌第131巻第10号

日本医師会雑誌第131巻第10号 B C 100 12 11 13 3 C 4 C Q&A B C 54 B B B B Q&A B B HBV 20 HBV B B B B HBV HBV HBV HBV 2 HBV HBV HBV A HBV HBV HBV HBV HBV Q37 HBV HBV HBV 1015 B B B Q51 B HBV B B HBV B HBV HBV HBV B B B HBV B HBV HBV

More information

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2) (1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46

More information

i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii

More information

…GŒÆ›u››‘KŒâ‚è_cs1.indd

…GŒÆ›u››‘KŒâ‚è_cs1.indd 1 1-1 4 1-2 a. b. c. d. e. 1-3 A. 4 B. 3 1-4 a. b. c. d. e. 1-5 1-6 4 1-7 a. b. c. d. e. 1-8 a. b. c. d. e. 1-9 1-10 A. 2 B. C. 1-11 a. / 2 b. / c. / d. / e. / 1-12 a. T b. c. M d. e. 1-13 1-14 1-15 16

More information

...J......1803.QX

...J......1803.QX 5 7 9 11 13 15 17 19 21 23 45-1111 48-2314 1 I II 100,000 80,000 60,000 40,000 20,000 0 272,437 80,348 82,207 81,393 82,293 83,696 84,028 82,232 248,983 80,411 4,615 4,757 248,434 248,688 76,708 6,299

More information

(1) (1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4) (5) (6) (7) (1) (1) (2) (3) (1) (2) (3) (4) (1) (2) (3) (4) (5) (1) (2) (3)

(1) (1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4) (5) (6) (7) (1) (1) (2) (3) (1) (2) (3) (4) (1) (2) (3) (4) (5) (1) (2) (3) (1) (2) (3) (1) Word (2) 1 (3) Excel (4) Excel (5) 2 (6) Power Point (7) 3 (8) HP HP HP (9) 1 HP (10) Excel (11) 2 (12) Excel (13) 3 (1) (2) (1) (1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4) (5) (6)

More information

ガイダンス資料.indd

ガイダンス資料.indd 2017 1. p.2 2. p.4 3. p.6 4. p.8 5. p.14 6. p.15 7. p.16 8. p.19 9. p.21 10. p.25 11. p.28 12. p.32 13. p.33 14. p.34 15. p.35 16. p.36 17. p.39 BOX8 06-6841-6025 info@machikanesai.com 1. 2017 6/28 1.

More information

untitled

untitled NTT 143-8540 5-21-16 Tel 03-3762-4151 Fax: 03-5493-5417 E-mail health@med.toho-u.ac.jp URL http://jhmtokyo.umin.jp 2 5 6 7 8 9 10 13 17 25 31 32 33 35 38 41 91 115 3 4 9 NPO 1999 5300 DPC BSC 9 2009 2

More information

cm H.11.3 P.13 2 3-106-

cm H.11.3 P.13 2 3-106- H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3

More information

Unknown

Unknown Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.2, No.3 July 2013 Report The 30 th Meeting of Japan Association of Breast and Thyroid Sonology... 1 Department of Organ

More information

Microsoft Word - 第302回プログラム最終版(H ).pdf

Microsoft Word - 第302回プログラム最終版(H ).pdf HP 24 10 15 24 10 24 302 374 24 11 10 9 00 16 30 20 A 1-2-27 TEL 06-6949-5151 602-8566 465 TEL 075-251-5620 FAX 075-251-5840 E-mail rad@koto.kpu-m.ac.jp http://www.jrs-kansai.jp/ PC 1 Macintosh PC Windows

More information

Microsoft Word - 要旨集3.doc

Microsoft Word - 要旨集3.doc RIKEN Symposium MHC Dynamics and functions of the MHC genes of animals from fish to human- Friday, Apl. 15, 2005 10:00-17:10 Okochi Hall, RIKEN (The Institute of Physical and Chemical Research) Contact:

More information

22 The 22nd Annual Meeting of the Japan Endocrine Pathology Society 2018 9 21 22 ( ) ( ) ( ) ( ) 22 30 9 21 22 2 22 8 14 4 5 65 12 29 30 9 22 2 Update 2018 2 770-8504 3-18-15 () () JR 30 440 25 4,000 JR

More information

B. 41 II: 2 ;; 4 B [ ] S 1 S 2 S 1 S O S 1 S P 2 3 P P : 2.13:

B. 41 II: 2 ;; 4 B [ ] S 1 S 2 S 1 S O S 1 S P 2 3 P P : 2.13: B. 41 II: ;; 4 B [] S 1 S S 1 S.1 O S 1 S 1.13 P 3 P 5 7 P.1:.13: 4 4.14 C d A B x l l d C B 1 l.14: AB A 1 B 0 AB 0 O OP = x P l AP BP AB AP BP 1 (.4)(.5) x l x sin = p l + x x l (.4)(.5) m d A x P O

More information

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG CLINICAL STUDIES OF UROGENITAL INFECTIONS WITH CHLAMYDIA TRACHOMA TIS Report 2. The Epidemiology of Chlamydial Infections in Okayama District in Japan and Detection of Antibodies to Chlamydiae in the Sera

More information

User's Guide

User's Guide magicolor 2300 DL 1800687-014B magicolor 2300 DL Windows TCP/IP Web URL http://www.minolta-qms.co.jp/support/userreg/index.html QMS MINOLTA-QMS magicolor MINOLTA-QMS, Inc. Minolta Peerless Systems Corporation

More information

16 16 16 1 16 2 16 3 24 4 24 5 25 6 33 7 33 33 1 33 2 34 3 34 34 34 34 34 34 4 34-1 - 5 34 34 34 1 34 34 35 36 36 2 38 38 41 46 47 48 1 48 48 48-2 - 49 50 51 2 52 52 53 53 1 54 2 54 54 54 56 57 57 58 59

More information

TAKAGI Hidenori 1986 2004 19 1911 4K269 701980 23K250 1986IBMJ. G. Bednorz K. A. Müller 30K 243 Bednorz Bednorz 30K 23K BednorzMüller1987 2 No.287 May

TAKAGI Hidenori 1986 2004 19 1911 4K269 701980 23K250 1986IBMJ. G. Bednorz K. A. Müller 30K 243 Bednorz Bednorz 30K 23K BednorzMüller1987 2 No.287 May ISSN 1349-1229 No. 287 May 2005 5 p8 SPOT NEWS p2 p10 p11 TOPICS 18 p12 p5 TAKAGI Hidenori 1986 2004 19 1911 4K269 701980 23K250 1986IBMJ. G. Bednorz K. A. Müller 30K 243 Bednorz Bednorz 30K 23K BednorzMüller1987

More information

JJRM5005/04.短報.責了.indd

JJRM5005/04.短報.責了.indd Jpn J Rehabil Med 2013 ; : 319.327 1 2 3 4 5 6 Survey of the Electronic Medical Recoding System Used in Kaifukuki Rehabilitation Wards Hidekazu SUGAWARA, 1 Tetsutaro YAHATA, 2 Hideto OKAZAKI, 3 Mitsuhiro

More information

?

? 240-8501 79-2 Email: nakamoto@ynu.ac.jp 1 3 1.1...................................... 3 1.2?................................. 6 1.3..................................... 8 1.4.......................................

More information

26 () () (1) (350ml ) (4 ) (2) 10 (3) RC

26 () () (1) (350ml ) (4 ) (2) 10 (3) RC 27 2015 27 2 3 ( 1.0 ) 1. 2. 2015 6 13 ( ) 2015 6 14 ( ) : (URL: http://www.kagakukan.sendai-c.ed.jp) 981 0903 4 1 Tel: 022-276-2201, Fax: 022-276-2204 3. : : : 2015 5 6 ( ) (ID ) 2015 5 11 ( ) () 2015

More information

後ろ.indd

後ろ.indd 2010 p.1-42 2010 7 The relation between food intake of pregnant women and fetal growth -case sutudy- Vol.11 No.3 p.481-4862010 11 The 10th Hamamatsu-kyungpook Joint Medical Symposium, p.54, School of Medicine,Kyugpook

More information

untitled

untitled 19 10 24 9 1... 2 2... 2 2-1... 2 2-2... 3 2-3... 3 2-4... 6 3... 7 3-1... 7 3-2... 7 3-3... 8 3-3-1... 8 3-3-2... 9 1... 9 2... 11 3... 13 4... 17 5... 18 3-3-3... 20 1... 20 20... 22 30... 27... 28 3-3-40...

More information

1

1 0 1 20122013 3 2 484.2 422.7 425.6 418.2 427.1 8.8 40.4 10.8 41.3 36.8 40.5 3.6 17.7 25.0 10.9 7.1 20.4 13.3 23.0 27.5 10.3 5.9 14.3 8.3 161.1 160.5 138.1 132.9 131.3 1.6 126.8 122.0 143.8 129.4 131.0

More information

研修コーナー

研修コーナー l l l l l l l Department of Obstetrics and Gynecology, Fukui Medical University, Fukui l l l l l l µ l β β l α l µ µ l l l l Department of Obstetrics and Gynecology, Gifu University School of Medicine,

More information

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio 7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine

More information

無印良品 2012 自転車 カタログ

無印良品 2012 自転車 カタログ 26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417

More information

News_Letter_No35(Ver.2).p65

News_Letter_No35(Ver.2).p65 OCIAL AFETY CIENCE No.35 2000.8 from Institute of Social Safety Science 10 11 17 11 19 17 181819 18 420-0042 5-9-1 JR 25 Tel 054-251-7100-1 - 10 10 I (1) 12 11 17 19 (2) 5-9-1 JR 25 II (1) 12 9 18 (2)

More information

untitled

untitled ---------- - 1 - ----- 1 Q1 5 Q2 5 Q3 5 Q4 6 Q5 6 Q6 7 Q7 7 Q8 7 Q9 8 Q10 : 8 10 Q1 10 Q2 11 Q3 11 12 Q4 12 Q5 HBs HBc _12 Q6 HBe 12 Q7 13 Q8 NAT 15 Q9 15 Q10 15 Q11 HBs 16 Q12 HBV DNA 16 Q13 17-2 - Q14

More information

第1回日本産婦人科

第1回日本産婦人科 e e TEL045-231-0960 TEL03-3433-1111 3360 4 2 1 1024768 OS RGB -15pins Dsub-15pins PowerPoint PC WindowsXPMicrosoft PowerPoint2002 Microsoft Power Point ( PC ) Windows USB CD-R PC 30 PC PC 36

More information

koji07-02.dvi

koji07-02.dvi 007 I II III 1,, 3, 4, 5, 6, 7 5 4 1 ε-n 1 ε-n ε-n ε-n. {a } =1 a ε N N a a N= a a

More information

<31302D8EC091488CA48B862D8E52936389698E7190E690B691BC2D3296BC976C2E706466>

<31302D8EC091488CA48B862D8E52936389698E7190E690B691BC2D3296BC976C2E706466> 77 1 1 1 Comparative analysis of training regimens between top European and Japanese women s youth handball teams with a focus on shooting Eiko Yamada 1 Hiroshi Aida 1 and Akira Nakagawa 1 Abstract In

More information

1997 1... 1... 2... 2... 2... 3... 6... 9... 9... 24... 39... 54... 69 4 1995 1996 A B C D 1 1 2 1 2 3 3 1 1 (1) (2) (3) 32 2 (1) (2) (3) 3 3 4 1 11 12 13 21 22 / / 23 5 4 4 1 9 1997 2 1 1 1 2 1 1 3 2

More information

rule2018.dvi

rule2018.dvi 30 2018 30 4 21 ( RC ) 1. 2. 2018 6 16 ( ) 2018 6 17 ( ) : (URL: http://www.kagakukan.sendai-c.ed.jp) 981 0903 4 1 Tel: 022-276-2201, Fax: 022-276-2204 3. : : : 2018 5 11 ( ) (ID ) 2018 5 14 ( ) () 2018

More information

14UNAIDS HIV 39% i 9 ii9iii UNAIDS x.9x.9x1= ?? UNAIDS % 77%8% 44.7x.77x.8x1=

14UNAIDS HIV 39% i 9 ii9iii UNAIDS x.9x.9x1= ?? UNAIDS % 77%8% 44.7x.77x.8x1= DeCEMBER, 17 No.34 HIV 169-73 1-1-1-13TEL 3-5937-4413:3 19:3 FAX 3-5937-443E-mail info@janpplus.jp http://janpplus.jp/!9-9-9!... 1-3 POSITIVE HIV/AIDS UNAIDS!... 4-5 JaNP+HIV Cafe Bar an opportunity...

More information

5.3 1. 2. 3. tert-tert 4. Enter 5. Delete 6. 7. Delete 8. Delete 9. [] [] 10. 11. 12. ID 40

5.3 1. 2. 3. tert-tert 4. Enter 5. Delete 6. 7. Delete 8. Delete 9. [] [] 10. 11. 12. ID 40 5 PowerPoint PowerPoint 2003 PowerPoint 2007 5.1 - tert- 1. 2. 3. 4. 5.2 PowerPoint 2007 PowerPoint 2007 Word 2007, Excel 2007 39 5.3 1. 2. 3. tert-tert 4. Enter 5. Delete 6. 7. Delete 8. Delete 9. []

More information

- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...

- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8... 取 扱 説 明 書 - - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...9...11 - - - - - - - - - - - - - - - - -

More information

「情報処理」を受講して身に付いたこと

「情報処理」を受講して身に付いたこと 14 1 40 (FD) 4 (1) (2) (3) Word, Excel, PowerPoint (4) 1 Power Point ph p Power Point Word Power Point Power Point Excel Word Excel, PowerPoint Word Excel Word Excel Excel Word Excel Power Point Power

More information

untitled

untitled 5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg

More information

i

i 14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7

More information

Journal of the Research Society for 15 years War and Japanese Medicine 1(2) May, 2001

Journal of the Research Society for 15 years War and Japanese Medicine 1(2) May, 2001 Journal of the Research Society for 15 years War and Japanese Medicine 1(2) May, 2001 Atomic Bomb and Japanese Medicine Soichi IIJIMA ( Key words; Nuclear Weapon, Atomic Bomb, Atomic Injury, Responsibility

More information

第59巻4,5号(10月号)/投稿規定・目次・表2・奥付・背

第59巻4,5号(10月号)/投稿規定・目次・表2・奥付・背 Special IssuePhysiology, psychology and treatment of eating disorders Reviews Originals Proceeding Case Report ob α α et al. et al et al Control of food intake Kyoichi Kishi, Kazuhito Rokutan, Takeshi

More information

64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k

64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k 63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5

More information

PG1501-PJ7816-CO36363-QuantStudio-3-and-5-brochure-Global-J.indd

PG1501-PJ7816-CO36363-QuantStudio-3-and-5-brochure-Global-J.indd Applied Biosystems QuantStudio 3 / QuantStudio 5 PCR PCR Applied Biosystems QuantStudio 3 QuantStudio 5 PCR Thermo Fisher Cloud 1 QuantStudio 3 and 5 Real-Time PCR Systems QuantStudio 3 and 5 Real-Time

More information

25 FD 2 2 8 72 74 74 81 96 109 109 113 116 121 125 125 127 127 128 131 132 136 136 137 137 137 137 162 162 163 164 164 173 177 182 185 186 187 187 188 191 192 193 193 195 195 197 200 201 203 204 10 205

More information

untitled

untitled http://www.mofa.go.jp/mofaj/toko/visa/index.html http://www.cn.emb-japan.go.jp/jp/01top.htm http://www.shanghai.cn.emb-japan.go.jp/ http://www.guangzhou.cn.emb-japan.go.jp/ http://www.shengyang.cn.emb-japan.go.jp/jp/index.htm

More information

Special IssueManagement principles in the critically ill - Review Case reports et al et al et al et al Nutritional management in critically ill patients Akiko Mano, Emiko Nakataki, Harutaka Yamaguchi,

More information

1

1 0 1 http://barrierfree.nict.go.jp/accessibility/index.html ( ) http://www.soumu.go.jp/joho_tsusin/w_access/index.html JIS X 8341-3 JISC JIS http://www.jisc 2 3 JIS X 8341-3 5.2e 1-62e) JIS X 8341-3 5.2e

More information

The Molecular Biology Society of Japan MBSJ NEWS 2013.11 No.106 http://www.mbsj.jp/ 2020 2020 7 2009 4 1 3 2011 1 3 1 2020 XLab 2 3 4 5 XLabExperiment, experience, exciting, expert Eva-Maria Neher 20

More information

22-1.indb

22-1.indb 22 1 27 4 20 24 1 2015 3 27 HLA 6 7 26 HLA 8 2015 11 18 HLA-QC 12 DNA Luminex 16 DNA SSO INNO-LiPA 18 DNA SSP 20 DNA SBT 22 FlowPRA 25 LABScreen 26 WAKFlow 28 30 DNA-QC 31 33 QCWS 35 総説 HLA T 37 13 44

More information

() 1 1 2 2 3 2 3 308,000 308,000 308,000 199,200 253,000 308,000 77,100 115,200 211,000 308,000 211,200 62,200 185,000 308,000 154,000 308,000 2 () 308,000 308,000 253,000 308,000 77,100 211,000 308,000

More information

steponeplus_bro_f-0210.indd

steponeplus_bro_f-0210.indd StepOnePlus / StepOne PCR PCR Applied Biosystems StepOnePlus StepOne PCR 1 Features At A Glance StepOne StepOnePlus / 48 96 FAM/SYBR Green dyes VIC/JOE dyes ROX dyes NED/TAMRA dyes 1. VeriFlex Block StepOnePlus

More information

2 ( ) USB USB USB USB-PS/2 PS/2 USB USB-PS/2 ( ) : Apple/MAC Wired Keyboard 600 Wired Desktop 600

2 ( ) USB USB USB USB-PS/2 PS/2 USB USB-PS/2 ( ) : Apple/MAC Wired Keyboard 600 Wired Desktop 600 Microsoft / Microsoft Wired Keyboard 500 Wired Keyboard 600 Comfort Curve Keyboard 2000 Wired Desktop 500 Wired Desktop 600 Wired Desktop 800 1 USB USB USB PS/2 PS/2 PS/2 M USB PS/2 0908 PartNo. X15-08209-01

More information

udc-2.dvi

udc-2.dvi 13 0.5 2 0.5 2 1 15 2001 16 2009 12 18 14 No.39, 2010 8 2009b 2009a Web Web Q&A 2006 2007a20082009 2007b200720082009 20072008 2009 2009 15 1 2 2 2.1 18 21 1 4 2 3 1(a) 1(b) 1(c) 1(d) 1) 18 16 17 21 10

More information

untitled

untitled 11-19 2012 1 2 3 30 2 Key words acupuncture insulated needle cervical sympathetick trunk thermography blood flow of the nasal skin Received September 12, 2011; Accepted November 1, 2011 I 1 2 1954 3 564-0034

More information